These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25426117)

  • 1. Erythropoietin and cancer: the unintended consequences of anemia correction.
    Debeljak N; Solár P; Sytkowski AJ
    Front Immunol; 2014; 5():563. PubMed ID: 25426117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The erythropoietin receptor in normal and cancer tissues.
    Jelkmann W; Bohlius J; Hallek M; Sytkowski AJ
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):39-61. PubMed ID: 18434185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin biology in cancer.
    Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
    Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin and Its Angiogenic Activity.
    Kimáková P; Solár P; Solárová Z; Komel R; Debeljak N
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin and the vascular wall: the controversy continues.
    Jelkmann W; Elliott S
    Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S37-43. PubMed ID: 22682530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin in cancer: the new face of an old friend.
    Megalakaki C
    J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
    Fandrey J; Dicato M
    Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study.
    Trincavelli ML; Da Pozzo E; Ciampi O; Cuboni S; Daniele S; Abbracchio MP; Martini C
    Int J Mol Sci; 2013 Jan; 14(2):2258-81. PubMed ID: 23348925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative.
    Chamorro ME; Wenker SD; Vota DM; Vittori DC; Nesse AB
    Biochim Biophys Acta; 2013 Aug; 1833(8):1960-8. PubMed ID: 23602701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study.
    Maggioni D; Nicolini G; Chiorazzi A; Meregalli C; Cavaletti G; Tredici G
    J Neurosci Res; 2010 Nov; 88(14):3171-9. PubMed ID: 20722073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative Erythropoietin Receptors in the Nervous System.
    Ostrowski D; Heinrich R
    J Clin Med; 2018 Feb; 7(2):. PubMed ID: 29393890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin, erythropoiesis and beyond.
    Chateauvieux S; Grigorakaki C; Morceau F; Dicato M; Diederich M
    Biochem Pharmacol; 2011 Nov; 82(10):1291-303. PubMed ID: 21782802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story?
    Calò LA; Davis PA; Piccoli A; Pessina AC
    Nephron Physiol; 2006; 103(3):p107-11. PubMed ID: 16554668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of erythropoietin on normal and neoplastic cells.
    Elliott S; Sinclair AM
    Biologics; 2012; 6():163-89. PubMed ID: 22848149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
    Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
    Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
    Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
    J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.